Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.
Neurotrophin treatment has so far failed to prolong the survival of individuals affected with amyotrophic lateral sclerosis (ALS), an incurable motoneuron degenerative disorder. Here we show that intracerebroventricular (i.c.v.) delivery of recombinant vascular endothelial growth factor (Vegf) in a SOD1(G93A) rat model of ALS delays onset of paralysis by 17 d, improves motor performance and prolongs survival by 22 d, representing the largest effects in animal models of ALS achieved by protein delivery. By protecting cervical motoneurons, i.c.v. delivery of Vegf is particularly effective in rats with the most severe form of ALS with forelimb onset. Vegf has direct neuroprotective effects on motoneurons in vivo, because neuronal expression of a transgene expressing the Vegf receptor prolongs the survival of SOD1(G93A) mice. On i.c.v. delivery, Vegf is anterogradely transported and preserves neuromuscular junctions in SOD1(G93A) rats. Our findings in preclinical rodent models of ALS may have implications for treatment of neurodegenerative disease in general.
Storkebaum
Erik
E
The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology (VIB), KU Leuven, Leuven B-3000, Belgium.
Lambrechts
Diether
D
Dewerchin
Mieke
M
Moreno-Murciano
Maria-Paz
MP
Appelmans
Saskia
S
Oh
Hideyasu
H
Van Damme
Philip
P
Rutten
Bart
B
Man
Wing Yan
WY
De Mol
Maria
M
Wyns
Sabine
S
Manka
David
D
Vermeulen
Kristel
K
Van Den Bosch
Ludo
L
Mertens
Nico
N
Schmitz
Christoph
C
Robberecht
Wim
W
Conway
Edward M
EM
Collen
Désiré
D
Moons
Lieve
L
Carmeliet
Peter
P
D000690:Amyotrophic Lateral Sclerosis / Q000235:genetics / Q000503:physiopathology*; D000818:Animals; D001370:Axonal Transport; D002470:Cell Survival / Q000187:drug effects; D004195:Disease Models, Animal; D006801:Humans; D007276:Injections, Intraventricular; D009046:Motor Neurons / Q000187:drug effects*; D009410:Nerve Degeneration / Q000503:physiopathology*; D009469:Neuromuscular Junction / Q000187:drug effects; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D013482:Superoxide Dismutase / Q000235:genetics; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology
D018696:Neuroprotective Agents; D011994:Recombinant Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C109415:SOD1 G93A protein; D013482:Superoxide Dismutase